GLP-1 Regulatory and Safety Guides
FDA approval timelines, compounding law, drug safety profiles, contraindications, and what the warning labels actually mean — explained without regulatory jargon.
Compounding regulation
Your Compounded GLP-1 Was Discontinued: A Step-by-Step Guide to Your Next Move
Your compounded semaglutide or tirzepatide refill was cancelled and nobody explained what to do next. Here are your five real options in 2026 — switch to brand, find a compliant compounder, change drugs, or taper off — what each costs, and the dose-handoff question that matters most.
FDA, Hims, and Novo: A Plain-English Timeline of the 2026 GLP-1 Compounding Cliff
The window for mass-market compounded semaglutide and tirzepatide closed across 2025. Here is the dated timeline — FDA shortage resolutions, OFA's lawsuit, the Hims-Novo blow-up, the warning-letter waves, and the April 2026 proposal that locks the door.
503A vs 503B Pharmacies for GLP-1s: What the Labels Actually Mean (2026)
Two statutory frameworks, one collapsed market. Here is exactly what 503A and 503B mean, why the distinction matters for compounded GLP-1s, and what each label can and cannot promise you in 2026.
GLP-1 Compounding Glossary: Key Terms Explained
503A, 503B, significant difference, SNAC, patient-specific compounding — the regulatory debate around compounded GLP-1s uses a specific vocabulary. Here is what each term means.
FDA GLP-1 Warning Letters Explained: What They Mean for Your Provider
FDA has sent 80+ warning letters to GLP-1 compounders and telehealth platforms since September 2025. Here is what a warning letter actually is, what violations were cited, and what it means for patients.
State Pharmacy Board Enforcement Against GLP-1 Compounders: A Patient Guide
FDA isn't the only regulator targeting compounded GLP-1s. State pharmacy boards, state attorneys general, and state health departments have taken enforcement actions that can shut down a provider faster than federal review. Here's what happened and what it means.
Hims Compounded GLP-1 Wind-Down: Timeline + Patient Options (May 2026)
On March 9, 2026, Hims settled with Novo Nordisk and agreed to stop advertising compounded GLP-1 products. Here is the full timeline of what Hims announced, what stops and when, what replaced it, and what options exist for existing patients.
Novo Nordisk's Lawsuits Against GLP-1 Compounders: What They Mean for Patients
Novo Nordisk sued 14+ compounders in February 2026 over a semaglutide patent. Hims settled. Mochi and Fella are still in court. Here is what the litigation means for patients on compounded semaglutide.
Mochi Health Compounded GLP-1 Status 2026: Lawsuit, Pharmacy Changes, and Operational Update
Mochi Health is still operating compounded semaglutide and tirzepatide as of May 2026. Two material risks: an active Eli Lilly patent lawsuit and the Washington State suspension of its original pharmacy partner. Here is the current picture.
Henry Meds Compounded GLP-1 Status 2026: No Warning Letter, 503A Framing, Current Pricing
Henry Meds continues offering compounded semaglutide and tirzepatide as of May 2026 under §503A. No FDA warning letter. No active litigation named in public records. Here is the current picture.
How to Switch From Compounded to Brand-Name GLP-1 (2026 Guide)
Your compounded supply is ending. Here is the exact process — new Rx, dose alignment, cost breakdown, and realistic timeline — for switching to Wegovy or Zepbound in 2026.
Is There a 503B-Compliant Compounded GLP-1 in 2026? The Honest Answer
503B outsourcing facilities lost legal authority to compound semaglutide and tirzepatide when shortages resolved. What providers calling their product '503B quality' actually mean — and what your real options are.
Safety and contraindications
GLP-1 Drugs Long-Term Safety: What We Know After 5+ Years of Data
Semaglutide has been in use since 2017 (Ozempic) and liraglutide since 2010. Five-plus-year safety data is now available. The picture is broadly reassuring — no major long-term safety signals have emerged that were not identified in Phase 3 trials — but a few questions remain under active monitoring.
GLP-1 Drugs and Thyroid Cancer: What the Black-Box Warning Actually Means
Every GLP-1 obesity drug carries a black-box thyroid warning. Here is what the animal data shows, what the human data shows, and who should not take these drugs because of the thyroid risk.
GLP-1 Drugs and Pancreatitis: What the Label Says vs What the Data Shows
GLP-1 prescribing labels include a pancreatitis caution. Early post-market case reports raised concern. Larger systematic analyses have not confirmed a causal relationship. Here is the current evidence picture.
GLP-1 Drugs and Gallbladder Disease: The Cholelithiasis Risk Explained
GLP-1 drugs are associated with increased gallstone formation — and a modest increase in acute cholecystitis. This is one of the few risks in the GLP-1 category where human evidence is stronger than animal evidence. Here is what the data shows.
GLP-1 Drugs and Kidney Function: What T2D Patients With CKD Need to Know
GLP-1 receptor agonists are generally safe in patients with chronic kidney disease and may provide kidney-protective benefits. Semaglutide showed reduced kidney disease progression in the FLOW trial. Here is what the evidence shows and what the dosing implications are.
GLP-1 Drugs and Hypoglycaemia: Who Is at Risk and How to Manage It
GLP-1 monotherapy rarely causes hypoglycaemia — the glucose-lowering mechanism is glucose-dependent, meaning it shuts off when glucose is low. The risk arises when GLP-1 therapy is combined with insulin or sulfonylureas.
GLP-1 Drug Interactions: What to Know Before Adding or Changing Medications
GLP-1 drugs have a specific interaction profile related to gastric emptying and oral drug absorption. The most clinically significant interactions are with oral medications that require rapid absorption, particularly immunosuppressants and some oral contraceptives.
GLP-1 Drugs and Eating Disorders: What Prescribers and Patients Should Know
GLP-1 drugs are generally not recommended in patients with active restrictive eating disorders — the appetite suppression can exacerbate restriction. The picture is more nuanced for binge-eating disorder, where emerging data suggests potential benefit.
GLP-1 Drugs and Liver Health: What the Evidence Shows for NAFLD and NASH
Non-alcoholic fatty liver disease (NAFLD) affects up to 80% of patients with obesity or type 2 diabetes. GLP-1 receptor agonists produce measurable reductions in liver fat and inflammation — the only drug class with consistent human evidence of benefit in NASH. Here is what the data shows.
Special populations
GLP-1 Drugs for Teenagers: What the FDA Has Approved and What the Evidence Shows
The FDA has approved semaglutide 2.4 mg (Wegovy) for adolescents aged 12 and older with obesity, and tirzepatide (Zepbound) for adolescents aged 12 and older. Adolescent GLP-1 use raises distinct questions about long-term development, growth, and appropriate prescribing thresholds.
GLP-1 Drugs in Type 1 Diabetes: Off-Label Use, What the Evidence Shows, and the Risks
GLP-1 receptor agonists are not FDA-approved for type 1 diabetes, but off-label use is increasing — particularly in adults with T1D and obesity who are not achieving glycaemic targets. The evidence is mixed. DKA risk from combined GLP-1 plus SGLT2 inhibitor use is a specific concern.
GLP-1 Drugs: All Current and Emerging FDA-Approved Indications
GLP-1 receptor agonists started as diabetes drugs. They now have FDA-approved indications covering weight management, cardiovascular risk reduction, heart failure, kidney protection, and sleep apnoea — with more pending. Here is the complete and current list of approved and emerging indications.
More
Is "Research-Grade" Semaglutide Safe? What "Not for Human Consumption" Actually Means
As compounded GLP-1s disappeared, some people started buying "research-grade" or "research use only" semaglutide and tirzepatide peptides online. This is decision support on why that is a fundamentally different and more dangerous risk category than a pharmacy-made product — what the label really means, what the testing actually finds, and the safer routes that are more affordable than they used to be.
Where to Get Compounded Semaglutide in 2026: What's Actually Left, and How to Tell Legitimate From Dangerous
If you are searching for where to buy compounded semaglutide or tirzepatide now, the honest answer is that the mass-market era is over and most products still advertised are not legally compliant. Here is what narrowly, legitimately remains, how to tell a compliant source from a dangerous one, and the safer routes most people end up taking.
Live trackers
- Compounding provider status tracker — real-time FDA shortage & enforcement status
- FDA warning letters tracker — all GLP-1-related warning letters